What are biosimilars?

Biosimilars are highly similar to the original biologics. Although it is impossible to produce an identical copy of any biologic medicine, a biosimilar must be proven to show no clinically meaningful differences from a reference product.

Do biosimilars have the same side effects and safety profile as the reference products?

Biosimilars must demonstrate that they have no clinically meaningful differences from their reference products in terms of safety and effectiveness. They are expected to work the same way as the original medicines.

How long have biosimilars been available?

The first biosimilar was approved in the United States in 2015.

Pfizer is committed to helping patients worldwide by developing and delivering high-quality biosimilar medications to patients who need them.